新西兰：2026年医院药品清单（英文）

Editor: Kaye Wilson, Doris Chong, Teresa Tayemail: enquiry@pharmac.govt.nzTelephone +64 4 460 4990Level 9, 40 Mercer StreetPO Box 10 254 Wellington 6143 Freephone Information Line0800 66 00 50 (9am – 5pm weekdays) Circulation You can register to have an electronicversion of the Pharmaceutical Schedule,Section H for Hospital Pharmaceuticals (linkto PDF copy) emailed to your nominatedemail address each month by subscribing atschedule.pharmac.govt.nz/subscribe. Production Typeset automatically from XML and TEX.XML version of the Schedule available fromschedule.pharmac.govt.nz/pub/HML Programmers Anrik Drenthemail: texschedule@pharmac.govt.nz©Pharmaceutical Management AgencyISSN 1179-3708 pdf This work is licensed under the CreativeCommons Attribution 4.0 International licence.In essence, you are free to copy, distributeand adapt it, as long as you attribute the workto Pharmac and abide by the other licenceterms. To view a copy of this licence, visit:creativecommons.org/licenses/by/4.0/.Attribution to Pharmac should be in writtenform and not by reproduction of the Pharmaclogo. While care has been taken in compilingthis Schedule, Pharmac takes no responsibilityfor any errors or omissions, and shall not beliable for any consequences arising there from. Part III Introducing PharmacThe Pharmaceutical Management Agency (Pharmac) makes decisions that help control Government spending on pharmaceuticals. This includes community pharmaceuticals, hospital pharmaceuticals, vaccines and increasingly, hospital medical devices. Pharmacnegotiates prices, sets subsidy levels and conditions, and makes decisions on changes to the subsidised list. Pharmac's role: “to secure for eligible people in need of pharmaceuticals, the best health outcomes that are reasonablyachievable from pharmaceutical treatment and from within the amount of funding provided.” Pae Ora (Healthy Futures) Act 2022 To ensure our decisions are as fair and robust as possible we use a decision-making process that incorporates clinical, economic andcommercial issues. We also seek the views of users and the wider community through consultation. The processes we generallyuse are outlined in our Operating Policies and Procedures.Further information about Pharmac and the way we make funding decisions can be found on the Pharmac website at https://pharmac.govt.nz/about. Glossary Units of Measure millimole........................................ mmolunit....................................................... u microgram....................................... mcgmilligram ........................................... mgmillilitre............................................... ml gram .................................................... gkilogram............................................. kginternational unit ................................. iu Abbreviations enteric coated................................... ECgranules........................................ gransinjection ..............................................injliquid ...................................................liqlotion................................................ lotnointment........................................... oint solution ............................................solnsuppository .................................suppostablet................................................. tabtincture..............................................tinc application ....................................... appcapsule ............................................ capcream............................................... crmdispersible .......................................dispeffervescent....................................... effemulsion ........................................ emul Guide to Section H listings Example PART I: GENERAL RULES Read the General Rules : https://pharmac.govt.nz/section-a. Phosphate Binding Agents ➥Restricted(RS1698)Initiation Only when prescribed for patients unable to swallow calcium carbonate tablets or where calcium carbonate tablets are inappropriate.. Antidiarrhoeals and Intestinal Anti-Inflammatory Agents Antipropulsives Rectal and Colonic Anti-Inflammatories ➥Restricted(RS1723)Initiation – Crohn's disease Both: 1 Mild to moderate ileal, ileocaecal or proximal Crohn's disease; and2 Any of the following:2.1 Diabetes; or2.2 Cushingoid habitus; or2.3 Osteoporosis where there is significant risk of fracture; or2.4 Severe acne following treatment with conventional corticosteroid therapy; or2.5 History of severe psychiatric problems associated with corticosteroid treatment; or2.6 History of major mental illness (such as bipolar affective disorder) where the risk of conventional corticosteroidtreatment causing relapse is considered to be high; or2.7 Relapse during pregnancy (where conventional corticosteroids are considered to be contraindicated). Initiation – Collagenous and lymphocytic colitis (microscopic colitis)Patient has a diagnosis of mi